TP53 and neoplasm: Preclinical models demonstrate that restoration of wild-type TP53 function using MDM2 inhibitors (e.g., nutlin-3a) can reinstate T-cell activity and reduce tumor-promoting inflammation, offering another potential radiosensitization strategy [59].